{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:51Z","timestamp":1740134931409,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1182\/blood.2023021817","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T15:31:17Z","timestamp":1698939077000},"page":"1504-1506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Toward rational therapy for mantle cell lymphoma"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-2876","authenticated-orcid":false,"given":"Mark A.","family":"Murakami","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2023110215311424200_bib1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.2023020211","article-title":"CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma","volume":"142","author":"Decombis","year":"2023","journal-title":"Blood"},{"unstructured":"NCCN Guidelines for B-Cell Lymphomas Version 5.2023. NCCN Guidelines. 2023. Accessed 26 July 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf.","key":"2023110215311424200_bib2"},{"issue":"5","key":"2023110215311424200_bib3","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"2023110215311424200_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023110215311424200_bib5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023110215311424200_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"24","key":"2023110215311424200_bib7","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023110215311424200_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"suppl\u00a01","key":"2023110215311424200_bib9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2021-151831","article-title":"Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen) [abstract]","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023110215311424200_bib10","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J\u00a0Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/18\/1504\/2087271\/blood_bld-2023-021817-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/18\/1504\/2087271\/blood_bld-2023-021817-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T15:31:24Z","timestamp":1698939084000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/18\/1504\/498492\/Toward-rational-therapy-for-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":10,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021817","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}